Rosiglitazone, a Ligand to PPAR, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation

Figure 4

Effect of rosiglitazone (RGZ) on aortic angiotensin II type 1 (AT₁R) (a), angiotensin II type 2 (AT₂R) (b), and Mas (c) receptor expression. The images show representative western blots. The protein expression was evaluated in homogenate of aorta from sham or aortic coarctated (AoCo) rats treated with vehicle (V), rosiglitazone (5mg/kg, RGZ), or RGZ + bisphenol A diglycidyl ether (120 mg/kg, RGZ+BADGE). The values represent the mean ± SEM (n=6 animals per group). One-way analysis of variance (ANOVA) post Tukey. ^∗P < 0.05 Sham-V vs. AoCo-V, ^#P < 0.05 AoCo-V vs. AoCo-RGZ, and ^&P < 0.05 AoCo-RGZ vs. AoCo-RGZ+BADGE. ND: not detected.

(a)

(b)

(c)